Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

For Example: Acquisitive Allergan buys micro-cap NASH biotech Tobira months after trial miss

paid top dollar for the biotech despite its sliding share price, with Allergan stumping an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs). All in, this could be worth $1.69 billion. The biotech was worth $4.74 last night, but jumped by more than 600% premarket to $33 a share.

Despite the recent trial setbacks, Allergan and Tobira are both confident of moving forward with late-stage testing for CVC in NASH, adding Allergan to a growing list of pharmas and biotechs looking to get in on a disease that could yield $4 billion in peak annuals for the more successful meds.

https://www.fiercebiotech.com/biotech/acquisitive-allergan-buys-micro-cap-nash-biotech-tobira-months-after-trial-miss

The point here is although Nash Pharmaceuticals is a micro-cap startup, it's going after thee hottest pharma industry drugs to date (NASH), and with it's pipeline ramping up, Big Pharma could step in with a financial deal before Nash Pharma even gets a Phase II trial off the ground.

It is here where the pharmaceutical industry shifts gears from looking at the scientific potential of a drug candidate and becomes squarely focused on the commercial potential. Here Big Pharma has never been so interested in (and so dependent upon) the junior pharma companies doing the majority of such research.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145033711

Micro-cap Tobira was bought out for 1.7 Billion @ the failed Phase II stage.

Back in July, Tobira Therapeutics fell by about half in premarket trading on news that its Phase IIb trial to treat nonalcoholic steatohepatitis (NASH) using its cenicriviroc (CVC) candidate failed to meet the primary endpoint.

/////AMG